
Cook County conducting study in Dixmoor on a workaround route for when trains block railroad crossings
To address long delays caused by stalled freight trains blocking rail crossings in Dixmoor, Cook County is funding a feasibility study for a potential roadway under Interstate 57 to help relieve congestion on Western Avenue.
The study, which began in August, is evaluating building a roadway within an existing right of way along Calumet Avenue between 141st Street and 143rd Street, according to Jesse Elam, director of strategic planning and policy for the Cook County Department of Transportation and Highways.
'Anything beats nothing,' Dixmoor Mayor Fitzgerald Roberts said. 'So the grant is doing a study on it, where we can pretty much make a throughway to get around these trains. I think it's a great move and I have great respect that they're trying to help us with this. It's been going on for so many years.'
The county earmarked $95,000 for the study, funded through Invest in Cook, a grant program that supports transportation projects at different stages including planning, engineering, land acquisition and construction, according to the county's website.
Although the village applied for the grant, Elam said the county is handling the study directly under an existing consulting contract, rather than going through the typical grant approval process.
The study is funded with state motor fuel tax revenues shared with the county, Elam said.
Elam said the county has explored the feasibility of building a connecting roadway under the interstate and is now reviewing property records to determine ownership and how it might affect the project.
After the study is completed, the county will share the findings with the village and decide on next steps, Elam said.
'We want to get it done as fast as we can, but the property research part of it turned out a little more complicated than we hoped, so I think that's really the sort of critical path item there,' Elam said. 'So we hope to be able to wrap that up in the next couple months.'
The village applied for the grant in 2024 after identifying an unused right of way that could improve access to neighborhoods east of Western Avenue, Roberts said. The road is in disrepair, covered in gravel and overgrown weeds, he said.
'We looked at an old map that showed that we had Calumet Avenue going through there,' Roberts said. 'We went on to find out that one of the mayors back in the day sold it or something, but it's not on a tax roll. It hasn't been placed on a tax roll. So basically, we want our street back.'
The project aims to create an alternate route for residents and emergency vehicles, Elam said, particularly for those in mobile home parks along Western Avenue where residents are often trapped when trains block both rail crossings at the same time.
The roadway will provide a backdoor entrance to the Colonial Estates Mobile Home Park near 142nd Street and Western Avenue, Elam said.
If the roadway proves feasible, Roberts said the village will need assistance funding construction.
According to the county, the feasibility study will also help identify potential funding sources and grants for engineering and construction.
While blocked crossings impede residents at crossings on Wood Street and Robey Avenue, residents told the Daily Southtown the problem is worse along Western Avenue, where tracks intersect the road in the 139th and 145th blocks.
Roberts said the proposed route won't fully solve the problem, as there are other crossings without an easy route to get around the stalled trains, but called it a first step toward addressing an issue that has affected residents for years.
'We'll be able to get from one side to the other side when the train is there,' Roberts said. 'But it's not going to completely solve it because if we have, per se, two trains on the track, you're still gonna be blocked one way. So we're still gonna need help.'
There is no federal statute or regulation that sets a specific time limit on how long trains can block grade crossings, according to the Federal Railroad Administration. That limits the actions the agency can take.
Meanwhile, trains have become longer due to precision scheduled railroading — a strategy used by freight rail companies to boost profits, lower operating costs and streamline service, according to the Government Accountability Office.
Roberts said he plans to seek support from legislators to help secure funding for the route and others that would allow residents to bypass stalled trains.
'There's a lot of pieces to this, to make this project complete,' Roberts said. 'This is just the first phase of getting it off the ground.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn

Miami Herald
a day ago
- Miami Herald
This California company converted a diesel tugboat to electric power
CHULA VISTA, California - It took some work and cost a pretty penny, but a Chula Vista boatbuilding and repair company recently converted a tugboat from diesel power to all-electric at its shipyard that covers 1 million square feet of land and water on San Diego Bay. "Electrification in maritime is important," said Todd Roberts, president of Marine Group Boat Works. "We wanted to not just do it for ourselves, but to show others that there's a path forward and here's how you do it." The company bought a new tugboat and then replaced its two 400-horsepower diesel engines with a fully integrated electric operating system, complete with batteries and charging equipment. Named MARCO V, the refitted tug emits no greenhouse gases while delivering comparable horsepower and torque. Charged from a shore power connector at the shipyard, the electric vessel is used about 80 hours a month. The small harbor tugboat tows vessels to and from the Marine Group's boat lift piers and docks. It also transports crew members prior to their vessels being hauled or after they launch. The original diesel version cost about $300,000 and the company officials said it cost more than twice that amount to convert the tug to electric power. A grant of $470,400 from the state covered about 75% of the conversion costs. The grant is part of a massive $423 million trust overseen by the California Air Resources Board funded by Volkswagen after the carmaker admitted cheating on vehicle emissions tests a decade ago. The trust helps pay for a variety of projects to reduce the climate impacts from the transportation sector, including commercial marine vessels. Even with the grant, that's a lot of money to spend on a tugboat. It took more than 2,000 hours of company labor to remove the diesel engines and install the new system. "We invested heavily in this, which is consistent with our sustainability mantra here at the boat yard," Roberts said. "We've bought several pieces of expensive equipment that would have been cheaper had we left them diesel … We don't just talk sustainability, we do it." More than 85% of Marine Group's vehicles and forklifts are electric and the company plans to install a 750-kilowatt solar system later this year to support the construction of vessels. When completed, it will be the only solar-powered boatbuilder in California. Rules enacted by the Air Resources Board requires commercial harbor craft like tugboats and ferries to reduce their emissions by 2035. The regulations mandate that by 2035, diesel engines on existing vessels must be upgraded and new builds must have zero-emission propulsion systems. Marine Group officials wanted to demonstrate that converting similarly sized tugs from diesel to electric can be replicated by other companies, such as excursion boats and dinner cruises. "Our goal was to take a sample project that had a very common horsepower profile and and come up with an 'in box, off the shelf' solution for electrification," Roberts said. MARCO V was named after Marine Group paint supervisor Marco Vega, who has been with the company for 34 years. "We wanted to give a nod to the people who make this company possible and that's our employees," Roberts said. In business since 1986, Marine Group Boat Works is a full-service maritime vessel construction and repair company that covers more than 2,000 of dockage on San Diego Bay and employs 230 workers. The company also has a staff of about 25 at a second facility in Los Cabos, Mexico. MARCO V is the second electric tugboat in the area. The Port of San Diego last year unveiled the 82-foot eWolf, operated by Crowley Maritime Corporation, that escorts ships entering and leaving the Tenth Avenue Marine Terminal. Much larger than MARCO V, the eWolf is capable of speeds up to 12 knots and expects in its first 10 years of use to eliminate 3,100 metric tons of carbon dioxide from the port and surrounding South Bay communities such as Barrio Logan and National City. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.